

BRAWN BIOTECH LIMITED
(formally known as Brawn Pharmaceuticals Limited)
REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024
Telefax: 011-23275208; Email: solution@brawnbiotech.com; website: www.brawnbiotech.com
CIN:L74899DL1985PLC022468

Part I							
(Rs in Lacs)							
Statement of standalone Unaudited Results for the Quarter ended 30/09/2016							
S. No.	PARTICULARS	Quarter Ended	Quarter Ended	Quarter Ended	Half Year ended	Half Year ended	Year Ended
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
a.	Net Sales/ Income from operations (Net of Excise Duty)	1,280.83	1,448.96	1,218.77	2,729.79	2,176.87	4,562.24
b.	Other Operating Income	21.57	26.86	23.24	48.43	39.91	126.14
	Total income from operations (Net)	1,302.40	1,475.82	1,242.01	2,778.22	2,216.78	4,688.38
2	Expenses						
a.	Cost of materials Consumed	-	-	-	-	-	-
b.	Purchase of Stock in Trade	1,119.95	1,266.50	1,093.60	2,386.45	1,906.31	3,998.86
c.	Change in Inventories of Finised Goods, work-in-Progress and Stock-in-Trade	15.54	7.05	(12.35)	22.59	7.49	53.24
d.	Employee Benefits Expenses	49.48	44.65	40.67	94.13	74.87	186.18
e.	Depreciation and amortisation expenses	0.82	0.70	0.94	1.52	1.82	3.32
f.	Other Expenditure	97.20	119.55	79.59	216.75	135.82	307.52
	Total Expenses	1,282.98	1,438.45	1,202.45	2,721.43	2,126.31	4,549.12
3	Profit/ (loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	19.42	37.37	39.56	56.79	90.47	139.26
4	Other Income	-	0.55	-	0.55	0.39	0.80
5	Profit/ (Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)	19.42	37.92	39.56	57.34	90.86	140.06
6	Finance Cost	0.78	0.30	1.40	1.08	1.59	9.57
7	Profit/ (Loss) from ordinary activities after Finance Cost but before Exceptional Items (5+6)	18.64	37.62	38.16	56.26	89.27	130.49
8	Exceptional Items	57.60	-	-	57.60	-	-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	76.24	37.62	38.16	113.86	89.27	130.49
10	Tax Expenses (Provisions)	11.89	12.21	-	24.10	-	35.52
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	64.35	25.41	38.16	89.76	89.27	94.97
12	Extraordinary Items (net of tax expenses)	-	-	-	-	-	-
13	Net Profit(+)/ Loss(-) for the period (11-12)	64.35	25.41	38.16	89.76	89.27	94.97

14	Paid-up equity share capital (Face Value of the Share is Rs.10/- each)	300.03	300.03	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	342.33	277.98	282.99	342.33	282.99	252.57
16 i	Earnings Per Share (before extraordinary items)(not annualised):in Rs.						
	(a) Basic	2.14	0.85	0.94	2.99	0.94	3.17
	(b) Diluted	2.14	0.85	0.94	2.99	0.94	3.17
16 ii	Earnings Per Share (after extraordinary items)(not annualised):in Rs.						
	(a) Basic	2.14	0.85	0.94	2.99	0.94	3.17
	(b) Diluted	2.14	0.85	0.94	2.99	0.94	3.17

Notes:

- 1 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their Meeting held on 07 November, 2016.
- 2 An amount of Rs. 2,68,16,475/-, appearing under Non Current Assets of the Balance Sheet for the year ended 31.03.2016, is under long pending litigation and as per views of the Board of Directors a provision for Bad and Doubtful Debts can be considered for such amount in the current Financial Year.
- 3 The Statutory Auditors have carried out a Limited Review of the Financial Results for the Quarter ended 30th September, 2016.
- 4 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting.
- 5 Figures of the previous periods have been re-grouped, wherever necessary, to conform to the current periods classification.
- 6 As per the agreement, actual amount of currency adjustment passed in the books of accounts on 30 September 2016, covering period from 01 July 2016 to 30 September 2016.

For and on behalf of the Board

Place: New Delhi

Date: 07.11.2016

(DIRECTOR)

BRAWN BIOTECH LIMITED
(formally known as Brawn Pharmaceuticals Limited)
REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024

		(Rs in Lacs)	
Standalone / Consolidated Statement of Assets and Liabilities		As at 30.09.2016	As at 31.03.2016
Particulars		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	300.03	300.03
	(b) Reserves and surplus	348.46	252.57
	Sub-total - Shareholders' funds	648.49	552.60
2	Non-current liabilities		
	(a) Long-term borrowings	-	4.84
	(b) Deferred Tax Liabilities (net)	-	-
	(c) Long-term provisions	7.77	7.77
	Sub-total - Non-current liabilities	7.77	12.61
3	Current liabilities		
	(a) Short-term borrowings	-	-
	(b) Trade payables	354.51	495.26
	(c) Other current liabilities	149.89	175.05
	(d) Short-term provisions	0.24	159.43
	Sub-total - Current liabilities	504.64	829.74
	TOTAL - EQUITY AND LIABILITIES	1,160.90	1,394.95
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	26.43	23.68
	(b) Non-current investments	-	3.00
	(c) Deferred tax assets (net)	2.13	2.13
	(d) Long-term loans and advances	9.39	8.17
	(e) Other non-current assets	136.98	268.16
	Sub-total - Non-current assets	174.93	305.14
2	Current assets		
	(a) Inventories	26.95	49.54
	(b) Trade receivables	889.80	920.23
	(c) Cash and Bank Balances	49.45	17.37
	(d) Short-term loans and advances	19.77	102.67
	Sub-total - Current assets	985.97	1,089.81
	TOTAL - ASSETS	1,160.90	1,394.95

For and on behalf of the Board

Place: New Delhi

Date:

(DIRECTOR)